Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1991-7-17
pubmed:abstractText
Haemopexin receptors from mouse hepatoma (Hepa) cells were affinity-labelled by cross-linking to haem-125I-haemopexin complexes using two homo-[disuccinimidyl suberate (DSS) and 3,3'-dithiobis(succinimidyl propionate) (DTSSP)] and one hetero-[sulphosuccinimidyl 4-(p-maleimidophenyl)butyrate (sulpho-SMPB)] bifunctional cross-linking agents. Analysis of the cross-linked products by SDS/PAGE in the absence of reducing agents revealed that 125I-haemopexin was cross-linked specifically to a protein of apparent molecular mass 85-90 kDa. Upon reduction, haemopexin remained cross-linked to a protein of 20 kDa, suggesting that the murine haemopexin receptor has a subunit structure. Two subunits were identified: alpha (p65) and beta (p20). Furthermore, because haemopexin was cross-linked by all three agents to p20, the shortest cross-linker arm being 1.1 nm (11 A), we propose that the haem-haemopexin-binding site resides on this subunit. In addition, a cysteine residue of p20 is located near the haemopexin-binding site, since haemopexin, which has no free thiol groups, is cross-linked to this subunit by the hetero-bifunctional agent sulpho-SMPB. Exposure of Hepa cells to the tumour-promoting phorbol ester 4 alpha-phorbol 12-myristate 13-acetate (PMA) causes a rapid redistribution of haemopexin receptors from the cell surface to the cell interior. Within 2-4 min of incubation with 100 nM-PMA, there was an approx. 50% decrease in cell-surface haemopexin receptors, as judged by ligand binding at 0 degrees C and affinity labelling of the receptor. This time- and dose-dependent down-regulation was fully reversible within 60-90 min after removal of PMA, and the affinity of the remaining receptors was unaltered by PMA. The specificity of PMA was demonstrated by comparison with the non-tumour-promoter 4 alpha-phorbol, which did not affect any of the parameters examined. The amine H-7, a specific inhibitor of protein kinase C, antagonised the receptor redistribution effect of PMA, suggesting that the down-regulation of haemopexin receptors on the cell surface was a consequence of protein kinase C activation. The PMA-induced decrease in surface haemopexin receptors was due to a 2-fold increase in the rate of internalization (from 0.73 min-1 to 1.32 min-1), whereas the rate of exocytosis (0.6 min-1) was unchanged. PMA treatment, like binding of the natural ligand, haem-haemopexin, results in a lower steady-state level of surface haemopexin receptors independent of receptor synthesis, and the receptors were not degraded but were recycled back to the cell surface.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-164457, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-1964416, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-213318, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-2344614, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-2416309, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-2824268, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-2852010, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-2987211, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-2991244, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-3007216, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-3017777, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-3021162, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-3021765, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-3031028, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-3036819, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-3119581, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-3129437, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-3223898, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-3223958, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-3479328, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-3479431, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-3498714, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-3568132, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-3884607, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-3891754, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-496916, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-5563759, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-6156003, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-6232463, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-6238627, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-6238960, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-6239622, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-6279628, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-6297785, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-6309781, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-6319386, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-6321473, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-6321514, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-6326098, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-6328486, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-6480598, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-7028734, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-7067914, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-728123, http://linkedlifedata.com/resource/pubmed/commentcorrection/1646599-7287740
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0264-6021
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
276 ( Pt 2)
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
417-25
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:1646599-Animals, pubmed-meshheading:1646599-Binding Sites, pubmed-meshheading:1646599-Cell Membrane, pubmed-meshheading:1646599-Cross-Linking Reagents, pubmed-meshheading:1646599-Down-Regulation, pubmed-meshheading:1646599-Endocytosis, pubmed-meshheading:1646599-Exocytosis, pubmed-meshheading:1646599-Hemopexin, pubmed-meshheading:1646599-Kinetics, pubmed-meshheading:1646599-Liver Neoplasms, Experimental, pubmed-meshheading:1646599-Macromolecular Substances, pubmed-meshheading:1646599-Mice, pubmed-meshheading:1646599-Models, Structural, pubmed-meshheading:1646599-Molecular Weight, pubmed-meshheading:1646599-Protein Kinase C, pubmed-meshheading:1646599-Receptors, Cell Surface, pubmed-meshheading:1646599-Receptors, Peptide, pubmed-meshheading:1646599-Tetradecanoylphorbol Acetate
pubmed:year
1991
More...